1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Oncology Companion Diagnostic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Polymerase Chain Reaction (PCR)
  • 1.2.3 Next-Generation Sequencing (NGS)
  • 1.2.4 Immunohistochemistry (IHC)
  • 1.2.5 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
  • 1.2.6 Others
• 1.3 Market by Application
  • 1.3.1 Global Oncology Companion Diagnostic Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Hospital
  • 1.3.3 Pathology/Diagnostic Laboratory
  • 1.3.4 Academic Medical Center
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Oncology Companion Diagnostic Market Perspective (2016-2027)
• 2.2 Oncology Companion Diagnostic Growth Trends by Regions
  • 2.2.1 Oncology Companion Diagnostic Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Oncology Companion Diagnostic Historic Market Share by Regions (2016-2021)
  • 2.2.3 Oncology Companion Diagnostic Forecasted Market Size by Regions (2022-2027)
• 2.3 Oncology Companion Diagnostic Industry Dynamic
  • 2.3.1 Oncology Companion Diagnostic Market Trends
  • 2.3.2 Oncology Companion Diagnostic Market Drivers
  • 2.3.3 Oncology Companion Diagnostic Market Challenges
  • 2.3.4 Oncology Companion Diagnostic Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Oncology Companion Diagnostic Players by Revenue
  • 3.1.1 Global Top Oncology Companion Diagnostic Players by Revenue (2016-2021)
  • 3.1.2 Global Oncology Companion Diagnostic Revenue Market Share by Players (2016-2021)
• 3.2 Global Oncology Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Oncology Companion Diagnostic Revenue
• 3.4 Global Oncology Companion Diagnostic Market Concentration Ratio
  • 3.4.1 Global Oncology Companion Diagnostic Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Oncology Companion Diagnostic Revenue in 2020
• 3.5 Oncology Companion Diagnostic Key Players Head office and Area Served
• 3.6 Key Players Oncology Companion Diagnostic Product Solution and Service
• 3.7 Date of Enter into Oncology Companion Diagnostic Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Oncology Companion Diagnostic Breakdown Data by Type

• 4.1 Global Oncology Companion Diagnostic Historic Market Size by Type (2016-2021)
• 4.2 Global Oncology Companion Diagnostic Forecasted Market Size by Type (2022-2027)

5 Oncology Companion Diagnostic Breakdown Data by Application

• 5.1 Global Oncology Companion Diagnostic Historic Market Size by Application (2016-2021)
• 5.2 Global Oncology Companion Diagnostic Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Oncology Companion Diagnostic Market Size (2016-2027)
• 6.2 North America Oncology Companion Diagnostic Market Size by Type
  • 6.2.1 North America Oncology Companion Diagnostic Market Size by Type (2016-2021)
  • 6.2.2 North America Oncology Companion Diagnostic Market Size by Type (2022-2027)
  • 6.2.3 North America Oncology Companion Diagnostic Market Size by Type (2016-2027)
• 6.3 North America Oncology Companion Diagnostic Market Size by Application
  • 6.3.1 North America Oncology Companion Diagnostic Market Size by Application (2016-2021)
  • 6.3.2 North America Oncology Companion Diagnostic Market Size by Application (2022-2027)
  • 6.3.3 North America Oncology Companion Diagnostic Market Size by Application (2016-2027)
• 6.4 North America Oncology Companion Diagnostic Market Size by Country
  • 6.4.1 North America Oncology Companion Diagnostic Market Size by Country (2016-2021)
  • 6.4.2 North America Oncology Companion Diagnostic Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Oncology Companion Diagnostic Market Size (2016-2027)
• 7.2 Europe Oncology Companion Diagnostic Market Size by Type
  • 7.2.1 Europe Oncology Companion Diagnostic Market Size by Type (2016-2021)
  • 7.2.2 Europe Oncology Companion Diagnostic Market Size by Type (2022-2027)
  • 7.2.3 Europe Oncology Companion Diagnostic Market Size by Type (2016-2027)
• 7.3 Europe Oncology Companion Diagnostic Market Size by Application
  • 7.3.1 Europe Oncology Companion Diagnostic Market Size by Application (2016-2021)
  • 7.3.2 Europe Oncology Companion Diagnostic Market Size by Application (2022-2027)
  • 7.3.3 Europe Oncology Companion Diagnostic Market Size by Application (2016-2027)
• 7.4 Europe Oncology Companion Diagnostic Market Size by Country
  • 7.4.1 Europe Oncology Companion Diagnostic Market Size by Country (2016-2021)
  • 7.4.2 Europe Oncology Companion Diagnostic Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Oncology Companion Diagnostic Market Size (2016-2027)
• 8.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Type
  • 8.2.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Application
  • 8.3.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Oncology Companion Diagnostic Market Size by Region
  • 8.4.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Oncology Companion Diagnostic Market Size (2016-2027)
• 9.2 Latin America Oncology Companion Diagnostic Market Size by Type
  • 9.2.1 Latin America Oncology Companion Diagnostic Market Size by Type (2016-2021)
  • 9.2.2 Latin America Oncology Companion Diagnostic Market Size by Type (2022-2027)
  • 9.2.3 Latin America Oncology Companion Diagnostic Market Size by Type (2016-2027)
• 9.3 Latin America Oncology Companion Diagnostic Market Size by Application
  • 9.3.1 Latin America Oncology Companion Diagnostic Market Size by Application (2016-2021)
  • 9.3.2 Latin America Oncology Companion Diagnostic Market Size by Application (2022-2027)
  • 9.3.3 Latin America Oncology Companion Diagnostic Market Size by Application (2016-2027)
• 9.4 Latin America Oncology Companion Diagnostic Market Size by Country
  • 9.4.1 Latin America Oncology Companion Diagnostic Market Size by Country (2016-2021)
  • 9.4.2 Latin America Oncology Companion Diagnostic Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Oncology Companion Diagnostic Market Size (2016-2027)
• 10.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Type
  • 10.2.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Application
  • 10.3.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Oncology Companion Diagnostic Market Size by Country
  • 10.4.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Agilent Technologies, Inc.
  • 11.1.1 Agilent Technologies, Inc. Company Details
  • 11.1.2 Agilent Technologies, Inc. Business Overview
  • 11.1.3 Agilent Technologies, Inc. Oncology Companion Diagnostic Introduction
  • 11.1.4 Agilent Technologies, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.1.5 Agilent Technologies, Inc. Recent Development
• 11.2 Illumina, Inc.
  • 11.2.1 Illumina, Inc. Company Details
  • 11.2.2 Illumina, Inc. Business Overview
  • 11.2.3 Illumina, Inc. Oncology Companion Diagnostic Introduction
  • 11.2.4 Illumina, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.2.5 Illumina, Inc. Recent Development
• 11.3 Qiagen N.V.
  • 11.3.1 Qiagen N.V. Company Details
  • 11.3.2 Qiagen N.V. Business Overview
  • 11.3.3 Qiagen N.V. Oncology Companion Diagnostic Introduction
  • 11.3.4 Qiagen N.V. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.3.5 Qiagen N.V. Recent Development
• 11.4 Thermo Fisher Scientific Inc.
  • 11.4.1 Thermo Fisher Scientific Inc. Company Details
  • 11.4.2 Thermo Fisher Scientific Inc. Business Overview
  • 11.4.3 Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Introduction
  • 11.4.4 Thermo Fisher Scientific Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.4.5 Thermo Fisher Scientific Inc. Recent Development
• 11.5 F. Hoffmann-La Roche Ltd.
  • 11.5.1 F. Hoffmann-La Roche Ltd. Company Details
  • 11.5.2 F. Hoffmann-La Roche Ltd. Business Overview
  • 11.5.3 F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Introduction
  • 11.5.4 F. Hoffmann-La Roche Ltd. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
• 11.6 ARUP Laboratories
  • 11.6.1 ARUP Laboratories Company Details
  • 11.6.2 ARUP Laboratories Business Overview
  • 11.6.3 ARUP Laboratories Oncology Companion Diagnostic Introduction
  • 11.6.4 ARUP Laboratories Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.6.5 ARUP Laboratories Recent Development
• 11.7 Abbott
  • 11.7.1 Abbott Company Details
  • 11.7.2 Abbott Business Overview
  • 11.7.3 Abbott Oncology Companion Diagnostic Introduction
  • 11.7.4 Abbott Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.7.5 Abbott Recent Development
• 11.8 Myriad Genetics, Inc.
  • 11.8.1 Myriad Genetics, Inc. Company Details
  • 11.8.2 Myriad Genetics, Inc. Business Overview
  • 11.8.3 Myriad Genetics, Inc. Oncology Companion Diagnostic Introduction
  • 11.8.4 Myriad Genetics, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.8.5 Myriad Genetics, Inc. Recent Development
• 11.9 bioMérieux SA
  • 11.9.1 bioMérieux SA Company Details
  • 11.9.2 bioMérieux SA Business Overview
  • 11.9.3 bioMérieux SA Oncology Companion Diagnostic Introduction
  • 11.9.4 bioMérieux SA Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.9.5 bioMérieux SA Recent Development
• 11.10 Invivoscribe, Inc.
  • 11.10.1 Invivoscribe, Inc. Company Details
  • 11.10.2 Invivoscribe, Inc. Business Overview
  • 11.10.3 Invivoscribe, Inc. Oncology Companion Diagnostic Introduction
  • 11.10.4 Invivoscribe, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
  • 11.10.5 Invivoscribe, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Global Oncology Companion Diagnostic Scope and Market Size
Oncology Companion Diagnostic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oncology Companion Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others

Segment by Application
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Agilent Technologies, Inc.
Illumina, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.